Preclinical Drug Assessment
Preclinical Drug Assessment - Related Videos
09:39
Assessing Specificity of Anticancer Drugs In Vitro
0 Views •
Cited by 8 •
2016
The goal of this protocol is to assess specificity of anticancer drugs in vitro using mixed cultures containing both tumor and non-tumor cells.
09:25
Assessment of Ultrasonic Vocalizations During Drug Self-administration in Rats
0 Views •
Cited by 17 •
2010
Drug self-administration and ultrasonic vocalizations (USV) are used as behavioral assessments in animal research, but rarely in combination. The purpose of this article is to describe the advantages of recording USVs during drug self-administration procedures to assess affective responses to drug experience.
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
0 Views •
Cited by 23 •
2017
Implementation of an orthotopic model of renal cell carcinoma in immunocompetent mice affords the investigator a clinically-relevant system defined by the presence of a primary renal tumor and lung metastases in the same animal. This system can be used to preclinically test a variety of treatments in vivo.
08:07
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
0 Views •
Cited by 5 •
2023
This protocol provides methods for generating 3D engineered cardiac and skeletal muscle tissues and describes their use in preclinical drug screening modalities. The described methods utilize a magnetic sensing system to facilitate the simultaneous assessment of 24 tissues in parallel.
13:17
The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport
0 Views •
Cited by 55 •
2015
Here we describe a technique to cannulate the mesenteric lymph duct in rats which enables quantification of lipid and drug transport via the lymphatic system following intestinal delivery. The technique can be adapted to assess mesenteric lymph concentrations and/or transport of fluid, immune cells, peptides, proteins and lipophilic molecules.
FAQs
Pharmacodynamics links exposure to the biological effects produced by a candidate therapy. Researchers use biochemical and cell-based assays, along with animal studies, to examine whether the compound produces the intended response and to explore its mechanism of action. These findings help distinguish meaningful biological activity from nonspecific effects and support decisions about lead optimization.
Pharmacokinetic information shows how the body handles a compound over time. Measurements of absorption, distribution, metabolism, and elimination help researchers interpret whether observed effects correspond to the compound’s presence in the body and how long it remains available. This context supports dose selection, reveals potential exposure-related risks, and helps compare candidate compounds during development.
Dose-response analysis compares the amount of a candidate therapy with the magnitude of its biological effect or toxic response. Researchers use these relationships to identify doses that produce useful activity while monitoring for harmful effects. Examining both outcomes helps determine whether increasing exposure improves performance, creates unacceptable toxicity, or offers little additional benefit.
Biochemical and cell-based assays provide controlled settings for examining biological activity, molecular effects, and possible mechanisms of action. They can help researchers compare compounds and prioritize leads before advancing them to animal studies. Animal testing then adds information about pharmacodynamics, pharmacokinetics, dose response, and toxicity within a more integrated biological system.
A typical workflow combines biochemical or cell-based testing with animal studies, while examining biological activity, pharmacodynamics, pharmacokinetics, dose-response relationships, and toxicity. Results are interpreted together rather than in isolation. The evidence supports lead optimization, helps identify risks and mechanisms of action, and informs selection of a development candidate for possible clinical evaluation.
Findings from preclinical drug assessment provide evidence for deciding whether a candidate has sufficient activity and an acceptable safety profile to advance. Pharmacokinetic, pharmacodynamic, dose-response, and toxicity results help researchers identify potential risks and plan carefully monitored clinical trials. In biology, the same evidence also clarifies mechanisms that may shape later interpretation of treatment effects.